Bilone F, Roncari R
Psychiatric Service USL, Legnano-Nogara, Italy.
Curr Med Res Opin. 1988;11(1):45-7. doi: 10.1185/03007998809111130.
A double-blind controlled trial was carried out in 50 patients with anxiety neuroses to compare the effectiveness of metaclazepam, a recently developed benzodiazepine with anxiolytic activity, and bromazepam. Patients were allocated at random to receive treatment for 13 days with either 15 mg metaclazepam or 4 mg bromazepam per day, in 2 divided doses. The patients' anxiety status was assessed on entry and after 7 and 13 days of treatment by the physician, using the Hamilton multi-factorial rating scale, and by the patients, using a self-assessment rating scale. Both drugs produced a highly significant reduction in mean total scores, improvement being evident by the Day 7 assessment. Correlation between scores on the two scales was significant at all time points. Metaclazepam, however, was rated as producing a significantly greater improvement from baseline than with bromazepam on the self-rating scale.
对50例焦虑性神经症患者进行了一项双盲对照试验，以比较最近研制的具有抗焦虑活性的苯二氮䓬类药物美他氯氮䓬和溴西泮的疗效。患者被随机分配，每天接受15毫克美他氯氮䓬或4毫克溴西泮治疗，分2次服用，为期13天。医生使用汉密尔顿多因素评定量表，患者使用自我评定量表，在入组时以及治疗7天和13天后对患者的焦虑状态进行评估。两种药物均使平均总分显著降低，在第7天评估时改善明显。在所有时间点，两种量表的评分之间均存在显著相关性。然而，在自我评定量表上，美他氯氮䓬被评为从基线起的改善程度明显大于溴西泮。
